Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Oncoimmunology"
DOI: 10.1080/2162402x.2019.1659096
Abstract: ABSTRACT Activation of Toll-like receptor 9 (TLR9) is known to foster innate and adaptive immune responses and thus improve immune-mediated control of malignant disease. Lefitolimod is a potent TLR9 agonist without chemical modification developed for… read more here.
Keywords: anti tumor; lefitolimod; tumor microenvironment; tumor ... See more keywords
Intraperitoneal injection of class A TLR9 agonist enhances anti–PD-1 immunotherapy in colorectal peritoneal metastases
Sign Up to like & getrecommendations! Published in 2022 at "JCI Insight"
DOI: 10.1172/jci.insight.160063
Abstract: Peritoneal metastases are associated with a low response rate to immune checkpoint blockade (ICB) therapy. The numbers of peritoneal resident macrophages (PRMs) are reversely correlated with the response rate to ICB therapy. We have previously… read more here.
Keywords: peritoneal metastases; tlr9 agonist; class tlr9; therapy ... See more keywords
TLR9 agonist lefitolimod to improve antitumor effect of checkpoint inhibitors in vivo.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e14625
Abstract: e14625Background: TLR9 agonists are potent activators of the immune system via induction of cellular and humoral responses. Preclinical and ongoing clinical studies support the use of TLR9 agonists for immunotherapeutic approaches. Lefitolimod/MGN1703 is a covalently-closed… read more here.
Keywords: lefitolimod improve; checkpoint inhibitors; tlr9 agonist; agonist lefitolimod ... See more keywords
Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13164081
Abstract: Simple Summary We evaluated the contribution of macrophages to the effect of combinatorial immunotherapeutic treatments based on TLR9 stimulation (with CpG-ODNs) and PD-1 blockade in an ovarian cancer preclinical model. We observed a strong reduction… read more here.
Keywords: anti antibody; tlr9 agonist; antibody; antibody domain ... See more keywords